Trials / Completed
CompletedNCT00524732
Assessment of the Reactogenicity of ADACEL® (TdcP Vaccine) in Children and Adolescents 7 to 19 Years of Age
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 7,156 (actual)
- Sponsor
- Sanofi Pasteur, a Sanofi Company · Industry
- Sex
- All
- Age
- 7 Years – 19 Years
- Healthy volunteers
- Accepted
Summary
To compare the reactogenicity of ADACEL® vaccine given at intervals of 2 to 9 years with the reactogenicity of ADACEL® vaccine given at an interval of 10 or more years following the last previous administration of vaccine containing Diphtheria and Tetanus Toxoids (referred to as TD/Td).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Tetanus and diphtheria toxoids and acellular pertussis | 0.5 mL, Intramuscular |
Timeline
- Start date
- 2004-09-01
- Primary completion
- 2004-12-01
- Completion
- 2005-09-01
- First posted
- 2007-09-05
- Last updated
- 2014-01-14
Locations
2 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT00524732. Inclusion in this directory is not an endorsement.